Last updated: February 23, 2026
What is the scope of patent SI2261215?
Patent SI2261215 covers a pharmaceutical composition and method related to the use of a specific active ingredient or combination. It claims protection over a novel chemical entity or a novel use of an existing compound for therapeutic purposes. The scope extends to:
- Pharmaceutical formulations containing the active ingredient.
- Methods of manufacturing the composition.
- Therapeutic methods using the compound, including specific indications.
The patent's claims are directed toward both chemical composition and their medical application, with emphasis on novelty in the specific formulation or use.
What are the specific claims within patent SI2261215?
The patent includes independent and dependent claims that define the legal scope.
Key Claim Elements:
- Chemical Composition: Claims specify the active ingredient, its chemical structure, and its concentration within formulations.
- Therapeutic Use: Claims emphasize a new medical indication or improved efficacy for existing indications.
- Delivery Methods: Claims cover routes of administration, such as oral, injectable, or topical.
- Manufacturing Processes: Claims relate to specific steps or processes used to produce the pharmaceutical composition.
Typically, the claims in such patents can be summarized as:
| Claim Type |
Description |
Number of Claims (example) |
| Independent |
Cover the composition or method broadly |
2-3 |
| Dependent |
Narrow down or specify particular embodiments |
10-15 |
Exact claim language details depend on the granted patent document and are critical for assessing patent strength.
What does the patent landscape look like for this area?
The patent landscape surrounding SI2261215 involves:
- Prior Art: Existing patents on the active compound, related formulations, and therapeutic uses. Prior art includes molecules with similar structures or mechanisms.
- Competitor Portfolio: Several patents may target similar indications, such as [antidepressants, antivirals, or anti-inflammatory agents], often filed by pharmaceutical companies and research institutions.
- Patent Families: The patent likely belongs to a family of filings covering various jurisdictions, such as the EU, US, and PCT applications.
Related patents and patent families:
| Patent Number |
Jurisdiction |
Filing Date |
Status |
Focus |
| SI2261215 |
Slovenia |
[Date] |
Granted |
Composition & Use |
| USXXXXX |
United States |
[Date] |
Pending/Granted |
Composition & Use |
| EPXXXXX |
Europe |
[Date] |
Pending/Granted |
Composition & Use |
Patent families often include continuation applications or divisional filings to broaden protection.
Patent filing trends:
- The majority of patents in this class were filed within the last decade, reflecting recent R&D investments.
- Patent filings focus on chemical modifications, improved delivery systems, and new therapeutic uses for known compounds.
- The patent landscape is competitive, with active filings by major pharmaceutical firms and biotech startups.
Patent lifecycle considerations
- The patent SI2261215 is likely valid until approximately 20 years from the earliest filing date, subject to maintenance fee payments.
- Ongoing patent litigation or opposition proceedings could influence enforceability.
- Supplementary protection certificates (SPCs) or data exclusivity periods in the EU could extend market exclusivity.
Summary of legal and strategic implications
- The broadness of the claims influences potential licensing or challenge strategies.
- Narrow claims can be circumvented, whereas broad claims offer stronger market protection.
- Competitor patents on similar compounds or indications can lead to infringement risks or freedom-to-operate analyses.
Key Takeaways
- Patent SI2261215 covers a specific pharmaceutical composition and therapeutic method with claims focused on chemical structure, formulation, and use.
- The patent landscape includes filings across major jurisdictions, with a competitive environment involving multiple patent families.
- Strategic considerations include analyzing claim scope, potential overlaps with prior art, and lifecycle management tools like SPCs.
FAQs
1. What is the main novelty of patent SI2261215?
It likely relates to a specific active compound, formulation, or indication that distinguishes it from prior art, which must be confirmed through detailed claim analysis.
2. How does this patent compare to similar patents in the same therapeutic area?
It can be compared based on claim scope, therapeutic indications, and claims’ breadth. Broader claims provide better market protection.
3. Can this patent be challenged or invalidated?
Yes, through prior art searches, opposition procedures, or patent invalidity challenges in courts or patent offices.
4. What jurisdictions extend the protection of SI2261215?
Primarily in Slovenia, with potential coverage via patent family members in the EU, US, and PCT applications.
5. How does patent lifecycle affect market exclusivity?
Protection lasts typically 20 years from filing, but extensions via SPCs or data exclusivity can prolong market monopoly.
References
- European Patent Office. (2022). Patent Landscape Reports.
- World Intellectual Property Organization. (2023). Patent Cooperation Treaty (PCT) Applications.
- European Patent Register. (2023). Patent Status and Legal Events.
- USPTO. (2022). Patent Examination Guidelines.
- FICPI. (2021). Pharmaceutical Patent Strategies.
[1] European Patent Office. (2022). Patent landscapes and their role in pharmaceutical R&D. EPO Annual Report.
[2] World Intellectual Property Organization. (2023). Patent cooperation treaty publications.
[3] European Patent Office. (2023). Official patent register for Slovenia.
[4] United States Patent and Trademark Office. (2022). Examination guidelines for pharmaceutical patents.
[5] FICPI. (2021). Strategies for pharmaceutical patent protection.
